Card-brand restrictions on peptide merchants are creating serious consequences throughout the payments industry. Learn how potential six-figure fines against acquiring banks and processors can lead to frozen funds, sudden account closures, and fewer processing options for peptide businesses.

Across the peptide, compounding, telehealth, wellness, and research industries, businesses are reporting a troubling pattern: terminated merchant accounts, frozen funds, rejected applications, excessive reserves, and sudden restrictions tied to peptide-related products. These actions can financially cripple a lawful business—sometimes without a meaningful explanation, individualized review, or opportunity to appeal. The time has come to determine whether these were independen

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.